Important note

This AI stock analysis for Eli Lilly and Company is not up to date. Creating and accessing our AI stock Analysis (powered by our data and Chat GPT) is only available for our premium users. Sign up to get access today!

Eli Lilly and Company - AI Stock Analysis

Analysis generated December 5, 2024

Eli Lilly and Company is a global pharmaceutical company headquartered in Indianapolis, Indiana. The company is renowned for its innovation in the healthcare sector, particularly in areas such as oncology, neuroscience, diabetes, and immunology. Eli Lilly has a robust portfolio of products that contribute significantly to its revenue, and the company continues to invest heavily in research and development to maintain and expand its market presence.

Fundamental Analysis

Examining the fundamentals, Eli Lilly's revenue for the last quarter was $11.4B. This marks an increase of 1.21% compared to the preceding quarter, signaling positive growth within a short time frame. More impressively, this is a 20.43% increase year-over-year, indicative of strong and consistent growth.

Notably, the net income for the last quarter was $970M. Although this shows a concerning 67.30% decrease from the previous quarter, it represents a staggering 1,790.42% increase compared to the same quarter last year. This significant year-over-year growth shows a strong recovery and potential resilience in the company's financial health.

However, the EBITDA for the last quarter was $0, showing a 100.00% decrease both sequentially and year-over-year. This could be a cause for concern, potentially reflecting operational difficulties or strategic shifts that impacted earnings before interest, taxes, depreciation, and amortization.

The current P/E ratio stands at 87.64, which is relatively high. This could indicate that the stock is overvalued in the market, suggesting a bearish outlook from certain perspectives. Investors may need to be cautious and consider whether the high P/E ratio reflects genuine market confidence or potential overvaluation.

Technical Analysis

The current stock price of Eli Lilly is $825.11, representing an increase of 2.54% over the past month and a notable 40.94% increase over the past year. These figures suggest a strong bullish trend both in the short and long term.

The SMA10 value is currently 801.93, which is higher than the previous SMA10 of 794.92, indicating a continuation of the upward trend in price movement. The Relative Strength Index (RSI) is 38.3, suggesting a neutral condition, meaning the stock is neither overbought nor oversold.

Alternative Data Analysis

Eli Lilly currently has 1,004 open positions, up by 18% in the last couple of months. This indicates that the company is in growth and expansion mode, typically a healthy sign. Employee sentiment is high with 83% having a positive outlook, further reinforcing the bullish sentiment within the company.

From a customer acquisition standpoint, the company's webpage saw approximately 4.3M visitors recently, a significant 33% increase, suggesting rising interest and potential customer base expansion. On the social media front, Eli Lilly has 40,000 followers on Instagram (up by 5%) and 140,000 followers on Twitter (down by 1%). The mixed engagement on social platforms provides a balanced overview but signals a need to consider social media trends carefully.

According to AltIndex’s AI score, which aggregates fundamental, technical, and alternative data, Eli Lilly has a score of 66, which indicates a buy signal. This synthetic measure provides a comprehensive view and suggests a positive outlook on the stock.

Conclusion

In conclusion, Eli Lilly and Company presents a mixed but predominantly positive stock profile. The fundamentals indicate strong revenue growth year-over-year, despite some concerns regarding net income and EBITDA figures. The technical analysis shows a bullish trend both in the short and long term, with the RSI indicating neutral conditions. Alternative data supports an optimistic outlook, with positive employee sentiment, increased job postings, and growing webpage visitors. Based on these combined factors, a recommendation would lean towards buying Eli Lilly & Company stock, albeit with careful monitoring of the company's earnings and valuation metrics.

Disclaimer: This AI stock analysis, generated by an experimental AI tool, is for informational purposes only and not financial advice. Information is based on publicly available data and may not always be accurate or current.